Laurent Pharmaceuticals Receives Approval from FDA to initiate its COVID-19 Phase 2 Clinical Trial
The Phase 2 study aims to evaluate the dual antiviral and inflammation-controlling effects of the company’s LAU-7b oral drug candidate against COVID-19 infection
Committed to developing treatments
for severe inflammatory
and fibrotic diseases
Events
Laurent Pharmaceuticals to participate at NACFC 2019, in Nashville TN, October 31st - November 2nd 2019
Laurent Pharmaceuticals to participate at BIO2019, in Philadelphia PA, June 3-6 2019